SCHEMBL12467343

SCHEMBL12467343

C/C=C(/NC(=O)c1cc(F)c2ccccc2c1OCc1ccc(C(F)(F)F)cn1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.35
GAA P10253 3/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.35
TACR1 P25103 1/20 0.34
KDM4E B2RXH2 2/20 0.34
RPS6KA3 P51812 1/20 0.34
KDM1A O60341 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
MAPT P10636 1/20 0.34
DRD3 P35462 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
LRRK2 Q5S007 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485706 0.84 CXCR2 (0.44) CXCR2MRGPRX4GAALMNAPOLB
SCHEMBL12728861 0.83 MRGPRX4 (0.43) CXCR2MRGPRX4GAALMNAPOLB
SCHEMBL12468141 0.82 CXCR2 (0.44) CXCR2MRGPRX4KDM4EKDM1AMAOA
SCHEMBL485734 0.81 CXCR2 (0.45) CXCR2MRGPRX4GAALMNAPOLB
SCHEMBL485133 0.81 CXCR2 (0.45) CXCR2MRGPRX4GAALMNAPOLB
SCHEMBL485907 0.81 CXCR2 (0.45) CXCR2MRGPRX4GAALMNAPOLB
SCHEMBL485687 0.79 MRGPRX4 (0.45) MRGPRX4LMNAPOLBMAPTFAAH
SCHEMBL485799 0.79 MRGPRX4 (0.45) MRGPRX4LMNAPOLBMAPTFAAH
SCHEMBL485695 0.79 CXCR2 (0.56) CXCR2RPS6KA3KDM1AMAOAMAOB
SCHEMBL485478 0.79 CXCR2 (0.56) CXCR2RPS6KA3KDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 US disclosed
US-20110184177-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184177-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 CXCR2 1/4885MRGPRX4 28/4885GAA 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.